Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31062502 | 0.80 | KDM4E (0.30) | LMNACYP3A4MAPTMAPK1 | |
| SCHEMBL26942083 | 0.77 | CCNB2 (0.34) | AXLPRKCILMNACYP3A4MAPT | |
| SCHEMBL3768772 | 0.74 | RECQL (0.34) | AXLPRKCILMNAMAPK1 | |
| SCHEMBL27979580 | 0.74 | AXL (0.31) | AXLPRKCI | |
| SCHEMBL30765145 | 0.74 | RECQL (0.34) | AXLPRKCILMNAMAPK1 | |
| SCHEMBL31145825 | 0.74 | KMO (0.30) | — | |
| SCHEMBL16335134 | 0.74 | DRD1 (0.36) | LMNAMAPTMAPK1 | |
| SCHEMBL875750 | 0.71 | KDM5A (0.33) | — | |
| SCHEMBL382323 | 0.69 | IDO1 (0.32) | — | |
| SCHEMBL4182232 | 0.69 | LMNA (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635553-B | Pyrimidine derivatives as kinase inhibitors and their therapeutic use | 常山凯捷健生物药物研发（河北）有限公司 | 2020-08-14 | — | — | CN | disclosed |
| EP-3261638-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| CN-107635553-A | Pyrimidine derivatives as kinase inhibitors and their therapeutic use | 南特生物科学公司 | 2018-01-26 | — | — | CN | disclosed |
| EP-3261638-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NantBioScience, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138527-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-3030081-A1 | PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES | Syngenta Participations AG (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015018431-A1 | PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-12 | — | — | WO | disclosed |
| US-4725607-A | MITICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-02-16 | — | — | US | disclosed |
| EP-0216541-A1 | Aryl pyridones | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-04-01 | — | — | EP | disclosed |
| CN-86106734-A | ARYL PYRIDONES | — | 1987-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | AXL 520/4885PRKCI 280/4885LMNA 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.